Prostaglandin-associated periorbitopathy syndrome (PAPS): Addressing an unmet clinical need

References

• Aihara M, Shirato S, Sakata R. Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost. Jpn J Ophthalmol. 2011;55(6):600–604. doi:10.1007/s10384-011-0075-6.
   PubMed Web of Science ®Google Scholar
• Manju M, Pauly M. Prostaglandin-associated periorbitopathy: a prospective study in Indian eyes. Kerala J Ophthalmol. 2020;32(1):36–40. doi:10.4103/kjo.kjo_90_19.
   Google Scholar
• Patradul C, Tantisevi V, Manassakorn A. Factors related to prostaglandin-associated periorbitopathy in glaucoma patients. Asia Pac J Ophthalmol. 2017;6(3):238–242. doi:10.22608/APO.2016108.
   PubMed Web of Science ®Google Scholar
• Kucukevcilioglu M, Bayer A, Uysal Y, et al. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost. Clin Exp Ophthalmol. 2014;42(2):126–131.doi:10.1111/ceo.12163.
   PubMed Web of Science ®Google Scholar
• Berke S. PAP: new concerns for prostaglandin use. Review of Ophthalmology 2012. Available at: reviewofophthalmology.com/article/pap-new-concerns-for-prostaglandin-use [Last accessed 28 January 2021].
   Google Scholar
• Sakata R, Shirato S, Miyata K, et al. Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost ophthalmic solution. Jpn J Ophthalmol. 2014;58(2):212–217.doi:10.1007/s10384-013-0299-8.
   PubMed Web of Science ®Google Scholar
• Oogi S, Nakakura S, Terao E, et al. One-year follow-up study of changes in prostaglandin-associated periorbital syndrome after switch from conventional prostaglandin F2alfa to omidenepag isopropyl. Cureus. 2020;12(8):e10064.doi:10.7759/cureus.10064.
   PubMed Web of Science ®Google Scholar
• Nakakura S, Terao E, Fujisawa Y, et al. Changes in prostaglandin-associated periorbital syndrome after switch from conventional prostaglandin F2α treatment to omidenepag isopropyl in 11 consecutive patients. J Glaucoma. 2020;29(4):326–328.doi:10.1097/IJG.0000000000001442.
   PubMed Web of Science ®Google Scholar
• Shah M, Lee G, Lefebvre DR, et al. A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features. PLoS ONE. 2013;8(5):e61638.doi:10.1371/journal.pone.0061638.
   PubMed Web of Science ®Google Scholar
• Rabinowitz MP, Katz LJ, Moster MR, et al. Unilateral prostaglandin-associated periorbitopathy: a syndrome involving upper eyelid retraction distinguishable from the aging sunken eyelid. Ophthalmic Plast Reconstr Surg. 2015;31(5):373–378.doi:10.1097/IOP.0000000000000351.
   PubMed Web of Science ®Google Scholar
• Sarnoff DS, Gotkin RH. Bimatoprost-induced chemical blepharoplasty. J Drugs Dermatol. 2015;14:472–477.
   PubMed Web of Science ®Google Scholar
• Sakata R, Shirato S, Miyata K, et al. Recovery from deepening of the upper eyelid sulcus after switching from bimatoprost to latanoprost. Jpn J Ophthalmol. 2013;57(2):179–184.doi:10.1007/s10384-012-0219-3.
   PubMed Web of Science ®Google Scholar
• Sakata R, Shirato S, Miyata K, et al. Incidence of deepening of the upper eyelid sulcus in prostaglandin associated periorbitopathy with a latanoprost ophthalmic solution. Eye. 2014;28(12):1446–1451.doi:10.1038/eye.2014.224.
   PubMed Web of Science ®Google Scholar
• Inoue K, Shiokawa M, Wakakura M, et al. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. J Glaucoma. 2013;22(8):626–631.doi:10.1097/IJG.0b013e31824d8d7c.
   PubMed Web of Science ®Google Scholar
• Miki T, Naito T, Fujiwara M, et al. Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy. PLoS ONE. 2017;12(7):e0181550.doi:10.1371/journal.pone.0181550.
   PubMed Web of Science ®Google Scholar
• Yaoeda K, Fukushima A, Shirakashi M, et al. Factors associated with fluctuations in repeated measurements of intraocular pressure using the Goldmann applanation tonometer in Japanese patients with primary open-angle glaucoma. Clin Ophthalmol. 2018;12:1473–1478. doi:10.2147/OPTH.S174277.
   PubMed Web of Science ®Google Scholar
• Shen W, Huang B, Yang J. Ocular surface changes in prostaglandin analogue-treated patients. J Ophthalmol. 2019;9798272. doi:10.1155/2019/9798272.
   PubMedGoogle Scholar
• Sweeney AR, Williams KJ, Dermarkarian CR, et al. Topical prostaglandin analog use is associated with increased failure rate of ptosis repair. Ophthalmology. 2020;27(2):276–278.doi:10.1016/j.ophtha.2019.09.007.
   Google Scholar
• Sano I, Takahashi H, Inoda S, et al. Shortening of interpupillary distance after instillation of topical prostaglandin analog eye drops. Am J Ophthalmol. 2019;206:11–16. doi:10.1016/j.ajo.2019.03.013.
   PubMed Web of Science ®Google Scholar
• Peplinski LS, Smith KA. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci. 2004;81(8):574–577. doi:10.1097/01.opx.0000141791.16683.4a.
   PubMed Web of Science ®Google Scholar
• Woodward DF, Wang JW, Stamer WD, et al. Antiglaucoma EP2 agonists: a long road that led somewhere. J Ocul Pharmacol Ther. 2019;35(9):469–474.doi:10.1089/jop.2019.0041.
   PubMed Web of Science ®Google Scholar
• Kirihara T, Taniguchi T, Yamamura K, et al. Pharmacologic characterization of omidenepag isopropyl, a novel selective EP2 receptor agonist, as an ocular hypotensive agent. Invest Ophthalmol Vis Sci. 2018;59(1):145–153.doi:10.1167/iovs.17-22745.
   PubMed Web of Science ®Google Scholar
• Aihara M, Lu F, Kawata H, et al. Pharmacokinetics, safety, and intraocular pressure-lowering profile of omidenepag isopropyl, a selective, nonprostaglandin, prostanoid EP2 receptor agonist, in healthy Japanese and Caucasian volunteers (Phase I study). J Ocul Pharmacol Ther. 2019;35(10):542–550.doi:10.1089/jop.2019.0044.
   PubMed Web of Science ®Google Scholar
• Ota T, Aihara A, Saeki T, et al. The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice. Br J Ophthalmol. 2007;91(5):673–676.doi:10.1136/bjo.2006.105585.
   PubMed Web of Science ®Google Scholar
• Doucette LP, Walter MA. Prostaglandins in the eye: function, expression, and roles in glaucoma. Ophthalmic Genet. 2017;38(2):108–116. doi:10.3109/13816810.2016.1164193.
   PubMed Web of Science ®Google Scholar
• Karli S, Ayala-Haedo JA, Feuer WJ, et al. Effect of prostaglandin analogs on matrix metalloproteinases and tissue inhibitor of metalloproteinases in eyelid muscle specimens. Clin Ophthalmol. 2018;12:2039–2046. doi:10.2147/OPTH.S178106.
   PubMed Web of Science ®Google Scholar
• Taketani Y, Yamagishi R, Fujishiro T, et al. Activation of the prostanoid FP receptor inhibits adipogenesis leading to deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy. Invest Ophthalmol Vis Sci. 2014;55(3):1269–1276.doi:10.11667/iovs.13-13589.
   PubMed Web of Science ®Google Scholar
• Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol. 2002;47(Suppl 1):S185–202. doi:10.1016/s0039-6257(02)00307-7.
   PubMed Web of Science ®Google Scholar
• Mohan S, Ahmad AS, Glushakov AV, et al. Putative role of prostaglandin receptor in intracerebral hemorrhage. Front Neurol. 2012;3:145. doi:10.3389/fneur.2012.00145.
   PubMedGoogle Scholar
• Dutkiewicz R, Albert DM, Levin LA. Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. Exp Eye Res. 2000;70(5):563–569. doi:10.1006/exer.1999.0819.
   PubMed Web of Science ®Google Scholar
• Fuwa M, Toris CB, Fan S, et al. Effects of a novel selective EP2 receptor agonist, omidenepag isopropyl, on aqueous humor dynamics in laser-induced ocular hypertensive monkeys. J Ocular Pharmacol Ther. 2018;34(7):531–537.doi:10.1089/jop.2017.0146.
   PubMed Web of Science ®Google Scholar
• Ida Y, Hikage F, Umetsu A, et al. Omidenepag, a non‑prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3‑L1 cells. Sci Rep. 2020;10:16018. doi:10.1038/s41598-020-72538-x.
   PubMed Web of Science ®Google Scholar
• Yan K, Gao LN, Cui YL, et al. The cyclic AMP signaling pathway: exploring targets for successful drug discovery (Review). Mol Med Rep. 2016;13(5):3715–3723.doi:10.3892/mmr.2016.5005.
   PubMed Web of Science ®Google Scholar
• Aihara M, Aung T, Bacharach J, et al. Omidenepag isopropyl ophthalmic solution for open-angle glaucoma and ocular hypertension: an update. Exp Rev Ophthalmol. 2021;16:243–250. doi:10.1080/17469899.2021.1935241.
   Web of Science ®Google Scholar
• Duggan S. Omidenepag isopropyl ophthalmic solution 0.002%: first global approval. Drugs. 2018;78(18):1925–1929. doi:10.1007/s40265-018-1016-1.
   PubMed Web of Science ®Google Scholar
• Ferro Desideri L, Cutolo CA, Barra F, et al. Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension. Drugs Today (Barc). 2019;55(6):377–384.doi:10.1358/dot.2019.55.6.2984806.
   PubMed Web of Science ®Google Scholar
• Aihara M, Lu F, Kawata H, et al. Phase 2, randomized, dose-finding studies of omidenepag isopropyl, a selective EP2 agonist, in patients with primary open-angle glaucoma or ocular hypertension. J Glaucoma. 2019;28(5):375–385.doi:10.1097/IJG.0000000000001221.
   PubMed Web of Science ®Google Scholar
• Aihara M, Lu F, Kawata H, et al. IOP-lowering efficacy and long-term safety of omidenepag isopropyl 0.002%, a selective EP2 agonist, in OAG and OHT. Poster PT-WT-127. Presented at World Glaucoma Congress (WGC) 2019, March 27-30, Melbourne, Australia. Available at: worldglaucomacongress.org/wp-content/uploads/ninja-forms/8/WGC-AYAME-RENGE-poster_Draft-2_12Mar2019.pdf [Last Accessed 18 September 2020].
   Google Scholar
• Yamamoto Y, Taniguchi T, Inazumi T, et al. Effects of the selective EP2 receptor agonist omidenepag on adipocyte differentiation in 3T3-L1 Cells. J Ocul Pharmacol Ther. 2020;36(3):162–169.doi:10.1089/jop.2019.0079.
   PubMed Web of Science ®Google Scholar
• Aihara M, Lu F, Kawata H, et al. Omidenepag isopropyl versus latanoprost in primary open-angle glaucoma and ocular hypertension: the Phase 3 AYAME study. Am J Ophthalmol. 2020;220:53–63. doi:10.1016/j.ajo.2020.06.003.
   PubMed Web of Science ®Google Scholar
• Clinical trials.gov. A Phase III study assessing the safety and efficacy of DE-117 ophthalmic solution compared with latanoprost ophthalmic solution in subjects with OAG or OHT (PEONY study). Available at: https://clinicaltrials.gov/ct2/show/NCT02981446 [Last Accessed 28 January 2021].
   Google Scholar
• Aihara M, Ropo A, Lu F, et al. Intraocular pressure‑lowering effect of omidenepag isopropyl in latanoprost non‑/low‑responder patients with primary open‑angle glaucoma or ocular hypertension: the FUJI study. Jpn J Ophthalmol. 2020;64(4):398–406.doi:10.1007/s10384-020-00748-x.
   PubMed Web of Science ®Google Scholar
• Terao E, Nakakura S, Nagata Y, et al. Evaluation of patterns and correlations of the degree of conjunctival hyperemia induced by omidenepag isopropyl 0.002% and ripasudil 0.4%. Cureus. 2020;12(9):e10368.doi:10.7759/cureus.10368.
   PubMed Web of Science ®Google Scholar
• Asia-Pacific Glaucoma Society (APGS). Asia-Pacific Glaucoma Guidelines [Internet]. Third ed. Amsterdam, The Netherlands: Kugler Publications. Available at: https://apglaucomasociety.org/Public/Public/Default.aspx [Last Accessed. 2016.
   Google Scholar
• European Glaucoma Society (EGS). Terminology and guidelines for glaucoma, 4th Edition - Chapter 3: treatment principles and options. Supported by the EGS Foundation. Br J Ophthalmol. 2017;101:130–195. doi:10.1136/bjophthalmol-2016-EGSguideline.003.
   PubMed Web of Science ®Google Scholar
• Kim JS, Blizzard S, Woodward JA, et al. Prostaglandin-associated periorbitopathy in children and young adults with glaucoma. Ophthalmol Glaucoma. 2020;3(4):288–294.doi:10.1016/j.ogla.2020.03.009.
   PubMedGoogle Scholar
• Inoue K, Inoue J, Kunimatsu-Sanuki S, et al. Short-term efficacy and safety on omidenepag isopropyl in patients with normal-tension glaucoma. Clin Ophthalmol. 2020;14:2943–2949. doi:10.2147/OPTH.S271789.
   PubMed Web of Science ®Google Scholar